BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 22265415)

  • 1. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.
    Freed-Pastor WA; Mizuno H; Zhao X; Langerød A; Moon SH; Rodriguez-Barrueco R; Barsotti A; Chicas A; Li W; Polotskaia A; Bissell MJ; Osborne TF; Tian B; Lowe SW; Silva JM; Børresen-Dale AL; Levine AJ; Bargonetti J; Prives C
    Cell; 2012 Jan; 148(1-2):244-58. PubMed ID: 22265415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.
    Pereira M; Glogova A; Haagsma J; Stewart J; Shepherd TG; Petrik J
    J Ovarian Res; 2023 Nov; 16(1):218. PubMed ID: 37986175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress.
    Kaymak I; Maier CR; Schmitz W; Campbell AD; Dankworth B; Ade CP; Walz S; Paauwe M; Kalogirou C; Marouf H; Rosenfeldt MT; Gay DM; McGregor GH; Sansom OJ; Schulze A
    Cancer Res; 2020 Jan; 80(2):189-203. PubMed ID: 31744820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic control of YAP and TAZ by the mevalonate pathway.
    Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
    Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer.
    Lu L; Huang W; Hu W; Jiang L; Li Y; Wu X; Yuan D; Li M
    Biochem Biophys Res Commun; 2019 Apr; 511(4):772-779. PubMed ID: 30833076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.
    Greenaway JB; Virtanen C; Osz K; Revay T; Hardy D; Shepherd T; DiMattia G; Petrik J
    Oncotarget; 2016 Jul; 7(30):47343-47365. PubMed ID: 27329838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells.
    Alizadeh J; Zeki AA; Mirzaei N; Tewary S; Rezaei Moghadam A; Glogowska A; Nagakannan P; Eftekharpour E; Wiechec E; Gordon JW; Xu FY; Field JT; Yoneda KY; Kenyon NJ; Hashemi M; Hatch GM; Hombach-Klonisch S; Klonisch T; Ghavami S
    Sci Rep; 2017 Mar; 7():44841. PubMed ID: 28344327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mevalonate Pathway and Human Cancers.
    Bathaie SZ; Ashrafi M; Azizian M; Tamanoi F
    Curr Mol Pharmacol; 2017; 10(2):77-85. PubMed ID: 26758953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.
    Moon SH; Huang CH; Houlihan SL; Regunath K; Freed-Pastor WA; Morris JP; Tschaharganeh DF; Kastenhuber ER; Barsotti AM; Culp-Hill R; Xue W; Ho YJ; Baslan T; Li X; Mayle A; de Stanchina E; Zender L; Tong DR; D'Alessandro A; Lowe SW; Prives C
    Cell; 2019 Jan; 176(3):564-580.e19. PubMed ID: 30580964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes.
    Massonnet B; Normand S; Moschitz R; Delwail A; Favot L; Garcia M; Bourmeyster N; Cuisset L; Grateau G; Morel F; Silvain C; Lecron JC
    Eur Cytokine Netw; 2009 Sep; 20(3):112-20. PubMed ID: 19825520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
    Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.
    Walsh CA; Akrap N; Garre E; Magnusson Y; Harrison H; Andersson D; Jonasson E; Rafnsdottir S; Choudhry H; Buffa F; Ragoussis J; Ståhlberg A; Harris A; Landberg G
    PLoS One; 2020; 15(7):e0236187. PubMed ID: 32692762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
    Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
    Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 regulates the mevalonate pathway in human glioblastoma multiforme.
    Laezza C; D'Alessandro A; Di Croce L; Picardi P; Ciaglia E; Pisanti S; Malfitano AM; Comegna M; Faraonio R; Gazzerro P; Bifulco M
    Cell Death Dis; 2015 Oct; 6(10):e1909. PubMed ID: 26469958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.
    Ingallina E; Sorrentino G; Bertolio R; Lisek K; Zannini A; Azzolin L; Severino LU; Scaini D; Mano M; Mantovani F; Rosato A; Bicciato S; Piccolo S; Del Sal G
    Nat Cell Biol; 2018 Jan; 20(1):28-35. PubMed ID: 29255172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing.
    Chen L; Ma MY; Sun M; Jiang LY; Zhao XT; Fang XX; Man Lam S; Shui GH; Luo J; Shi XJ; Song BL
    J Lipid Res; 2019 Oct; 60(10):1765-1775. PubMed ID: 31455613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
    Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
    Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers.
    Mokarram P; Alizadeh J; Razban V; Barazeh M; Solomon C; Kavousipour S
    Curr Mol Pharmacol; 2017; 10(2):86-114. PubMed ID: 26758947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.